![]()
- Peak Oil Closer Than IEA Forecasts Show: Report
- UK Most at Risk of Losing Top Credit Rating: Fitch
- GM CEO Starts Charm Tour at Opel in Germany
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
- Bad Debt Weighs on Barclays Earnings
- HSBC Operating Profit Beats, US Bad Debts Slip
- Fed's Tarullo Backs Surcharges to Limit Bank Size
- Look Ahead: 'Risk On' Sentiment Could Fuel Rally Further
- 'Modern Warfare 2': Biggest Entertainment Event?
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Future of Marketing
- Mad Mail: Buy the Berkshire Hathaway Split?
- European Commission Objects to Sun Micro-Oracle Deal
- GM CEO Starts Opel Charm Tour in Germany
- Framed for Porn – By a PC Virus
- A Year on, China's Stimulus Postpones its Problems
- Israel: Leader of Business Innovation
powered by digg
Abbott wins OK for drug-coated heart stent
Topics:Pharmaceuticals
Companies:Abbott Laboratories
Abbott Laboratories won U.S. approval to sell its drug-coated heart stent called Xience, the company said on Wednesday.
Xience is the newest entry in a multibillion-dollar market that includes devices sold by Johnson & Johnson , Boston Scientific and Medtronic Inc.
Abbott [ABT
Loading...
()
] said it plans to launch its stent immediately.
Copyright 2009 Reuters. Click for restrictions.
- Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
- Software, biotech firms, even banks are watching a particular Supreme Court argument today.
- From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
- The health care reform bill that passed the House on Saturday will have a much harder time in the Senate.
MORE FROM CNBC











